Frontlight ResearchEarly access
CompletedPhase 4
Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children
Key facts
- Who runs it
- Murdoch Childrens Research Institute
- Where
- Australia2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 130 people enrolled
- Started
- 5 Dec 2022
- Ended
- 17 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mometasone Furoate 50mcg Nasal Spray
- Sodium Chloride 0.9 % Nasal Spray
- Record updated
- 30 September 2025
Who can take part
- Age
- 3 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Each participant must meet all of the following criteria to be enrolled in this trial:
- Is between the ages of 3 and 12 years inclusive at the time of randomisation
- Has symptoms of Sleep Disordered Breathing (SDB) as determined by a Brouillette score ≥ -1 on telehealth/phone screening
- Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf
Who cannot take part
- Has a prior diagnosis of craniofacial, neuromuscular, syndromic or defined genetic disorders
- Has active tonsillitis or nasal infection (must be resolved prior to randomisation)
- Has used oral, intravenous, or intranasal steroids in the past 6 weeks. (Inhaled steroids for asthma will be allowed concomitantly during the study)
- Is known to require systemic steroids prior to the completion of the study treatment phase
- Has had treatment with any other investigational drug within 6 months prior to randomisation
- Has a history of tonsillectomy and/or adenoidectomy
- Has a history of haemorrhagic diathesis or recurrent (daily) or severe epistaxis
- Has a history of nasal surgery or trauma which has not fully healed
- Has a known hypersensitivity to the study drug or its formulation
- Has a BMI over the 97th centile for age and gender
- Participants meeting any of the following criteria will be excluded from the study:
- Is assessed to have stertor (snoring) while awake at rest
- Daily use of antihistamine or decongestant nasal sprays
- Is unable to provide consent without the aid of an interpreter
- In the opinion of the Investigator may be unable to follow the protocol
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
MIST+ is studying a nasal spray to see if it will reduce the need for surgery for snoring. Children aged 3-12 are invited to take part. Snoring affects up to 10% of children and can cause sleeping problems and concentration or behavioural issues in the daytime. Currently the most common treatment for snoring is surgery to remove the tonsils and/or adenoids, however many children wait a long time to see a specialist. This research is trying to find if nasal sprays can help children with snoring, and whether this can reduce the need for surgery.
The 2 groups in the trial
- Intranasal SteroidsTreatment being tested
Treatment: Mometasone Furoate 50mcg Nasal Spray
- Intranasal SalinePlacebo, for comparison
Treatment: Sodium Chloride 0.9 % Nasal Spray
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy of Intranasal Steroid for Children With Sleep-Disordered Breathing Non-Responsive to Initial Treatment With Intranasal Saline: A Randomized Trial
- Publications
- Record updated
- 30 September 2025